Amglidia
What Amglidia is used for
Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the ?-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Amglidia
- Active substance
- glibenclamide
- Disease area
- Diabetes Mellitus
- Medicine group
- Drugs used in diabetes
- ATC code
- A10BB01
- Marketing authorisation holder
- Ammtek
- Authorised in the EU since
- 2018
Official information
In India
- Glibenclamide: 175 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Amglidia used for?
Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children. Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the ?-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus.
What is the active substance in Amglidia?
Amglidia contains glibenclamide.
Who makes Amglidia?
The EU marketing authorisation holder is Ammtek.
Is Amglidia an orphan medicine?
Yes. Amglidia is designated an orphan medicine in the EU, for a rare disease (Diabetes Mellitus).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU